|
|||||
|
|
Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study |
|
| Authors: | Judith Neukirchen Michael Lauseker Sabine Blum Aristoteles Giagounidis Michael Lübbert Samuela Martino Sergio Siragusa Richard F Schlenk Uwe Platzbecker Wolf-Karsten Hofmann Katharina Götze Giuseppe A Palumbo Silvana Magrin Andrea Kündgen Carlo Aul Barbara Hildebrandt Joerg Hasford Guido Kobbe Rainer Haas Ulrich Germing |
| Institution: | 1. Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany;2. Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany;3. Department of Hematology, University Lausanne, Switzerland;4. Department of Hematology, Oncology and Clinical Immunology, St. Johannes Hospital, Duisburg, Germany;5. Department of Hematology and Oncology, Albert-Ludwigs-University, Freiburg, Germany;6. Department of Hematology, University of Palermo, Italy;g Department of Internal Medicine III, University Hospital Ulm, Germany;h Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany;i Department of Medicine III, University Hospital Mannheim, Germany;j Department of Medicine III, Division for Hematology and Oncology, Klinikum rechts der Isar, Technical University, Munich, Germany;k Department of Hematology, AOU “Policlinico – V. Emanuele”, Catania, Italy;l Division of Hematology and BMT Unit, V. Cervello Hospital, Palermo, Italy;m Department of Human Genetics, Heinrich-Heine-University, Düsseldorf, Germany |
| Abstract: | The revised IPSS (IPSS-R) was developed aiming at a better prognostication, taking into account patients treated with best supportive care. We herein validated this model on the basis of data from 1314 patients who received BSC only as well as patients who underwent induction chemotherapy (n = 214) or allogeneic transplantation (n = 167). We could demonstrate a clear distinction of the IPSS-R risk categories with regard to survival and risk of AML evolution in all patient cohorts. When comparing IPSS-R, IPSS, WHO prognostic scoring system (WPSS) and Duesseldorf score, the best results regarding the ability to predict survival were obtained by the IPSS-R. |
| Keywords: | MDS IPSS-R IPSS WPSS Prognosis Survival |
| 本文献已被 ScienceDirect 等数据库收录！ | |